Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase\u00e2 $ 3 GUIDEPOST CRC test

.Completing passions.S.K.: Supply as well as Various Other Possession Interests: Iylon, Lutris, MolecularMatch, Navire. Consulting or Advisory Part: AbbVie, Amal Rehabs, AstraZeneca/MedImmune, Bayer Health, Bicara Therapies, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Endeavor BioMedicines, Blaze Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Healthcare, Inivata, Ipsen, Iylon, Jacobio, Jazz Drugs, Lilly, Lutris, Merck, Mirati Rehabs, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Study Backing: Amgen (Inst), Collection BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Job: In The Past Pfizer. Stock and also Other Possession Rate Of Interests: Pfizer. J.P.: Work: Previously Pfizer. Supply and also Other Possession Stakes: Pfizer. F.C.: Consulting or Advisory Duty: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Research Study Backing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Part: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Research Study Financing: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Task: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Pharmaceutical, Terumo. H.S.W.: Consulting or Advisory Task: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapeutics, Erytech Pharma, Incyte, Merck KGaA, Oaktree Lifestyle Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Study Funding: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Study Financing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Pharmaceutical (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Pharmaceutical (Inst). H.S.: Employment: Pfizer. Supply and Other Possession Claims: Pfizer. X.Z.: Job: Pfizer. Stock and Other Possession Claims: Pfizer. Patents, Royalties, Various Other Intellectual Property: Johns Hopkins Educational Institution. P.H.: Employment: Pfizer. Supply and also Various Other Possession Claims: Pfizer. T.X.: Job: Pfizer. Stock as well as Other Possession Claims: Pfizer. R.Y.: Consulting or Advisory Task: Selection BioPharma/Pfizer, Mirati Rehabs, Zai Laboratory, Amgen. Study Financing: Collection BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapy (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or Advisory Function: Assortment BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapeutics, MSD, NeoPhore, Novartis, Ona Rehabs, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapy, Seagen Inc., Servier, Taiho Drug, Tessa Rehab, TheraMyc. Other Partnership: Amgen, Assortment Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Research UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Converse el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Rehabs, PeerView Institute for Medical Education And Learning, Pfizer, PharmaMar, Physicansu00e2 $ Education Resource, Sanofi-Aventis, Servier, Taiho Drug.